I help biotools (omics) companies with:
By applying roadmapping and resource-allocation best practices,
I catapult omics • Innovation to Commercialization (I2C) success.
With a focus on pinpointing missing pieces in the I2C puzzle,
I vet new business opportunities in relation to corporate growth plans.
Representative results include:
Beneficial collaborative alliances with preferred partners
Alignment between new product features and customer needs
Freedom-to-Operate (FTO) clearance, a valuable assessment to have even with an already strong patent portfolio
Catalyzing omics I2C for propelling precision testing and care